Email Alert | RSS

北京大学学报（医学版） ›› 2022, Vol. 54 ›› Issue (6): 1190-1195. doi: 10.19723/j.issn.1671-167X.2022.06.022

• 论著 • 上一篇    下一篇

药物相关颌骨骨坏死的病理特点及临床治疗策略

郭玉兴1,张建运2,王佃灿1,郭传瑸1,*()   

  1. 1. 北京大学口腔医学院·口腔医院口腔颌面外科，国家口腔医学中心，国家口腔疾病临床医学研究中心，口腔生物材料和数字诊疗装备国家工程研究中心，口腔数字医学北京市重点实验室，国家卫生健康委员会口腔医学计算机应用工程技术研究中心，国家药品监督管理局口腔生物材料重点实验室，北京 100081
    2. 北京大学口腔医学院·口腔医院口腔病理科，国家口腔医学中心，国家口腔疾病临床医学研究中心，口腔生物材料和数字诊疗装备国家工程研究中心，口腔数字医学北京市重点实验室，国家卫生健康委员会口腔医学计算机应用工程技术研究中心，国家药品监督管理局口腔生物材料重点实验室，北京 100081
  • 收稿日期:2020-03-19 出版日期:2022-12-18 发布日期:2022-12-19
  • 通讯作者: 郭传瑸 E-mail:guodazuo@sina.com
  • 基金资助:
    北京大学口腔医院青年科研基金(PKUSS20160115);国家自然科学基金(81900979)

Analysis of pathological characteristics of medication-related osteonecrosis of the jaw and discussion of clinical treatment strategies based on the pathological analysis results

Yu-xing GUO1,Jian-yun ZHANG2,Dian-can WANG1,Chuan-bin GUO1,*()   

  1. 1. Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices & Beijing Key Laboratory of Digital Stomatology & NHC Research Center of Engineering and Technology for Computerized Dentistry & NMPA Key Laboratory for Dental Materials, Beijing 100081, China
    2. Department of Oral Pathology, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices & Beijing Key Laboratory of Digital Stomatology & NHC Research Center of Engineering and Technology for Computerized Dentistry & NMPA Key Laboratory for Dental Materials, Beijing 100081, China
  • Received:2020-03-19 Online:2022-12-18 Published:2022-12-19
  • Contact: Chuan-bin GUO E-mail:guodazuo@sina.com
  • Supported by:
    the Research Foundation of Peking University School and Hospital of Stomatology(PKUSS20160115);the National Natural Science Foundation of China(81900979)

RICH HTML

   

PDF (PC)

摘要：

目的: 总结药物相关颌骨骨坏死(medication-related osteonecrosis of the jaw, MRONJ)标本病理特点，结合患者不同手术方案治疗效果进行综合分析，为临床工作中有效治疗MRONJ提供思路。方法: 收集2014年6月至2015年12月北京大学口腔医院口腔颌面外科采用颌骨刮治术和颌骨区段截骨术进行治疗的23例MRONJ患者临床病理资料，总结MRONJ病理特点，并结合手术治疗方式，探讨基于病理表现特征下的临床治疗策略。MRONJ诊断标准和疾病分期依据2014年美国口腔颌面外科学会专家共识进行判定。结果: 本组患者5例采用颌骨区段截骨治疗，均为Ⅲ期；18例采用颌骨刮治治疗，其中Ⅱ期5例，Ⅲ期13例。5例颌骨区段截骨术的MRONJ标本病理特征从浅至深分为炎症区、骨硬化区、骨反应带，为更好分析颌骨刮治术的标本病理表现特征，我们将仅包括炎症区的表现定义为Ⅰ类病理特征，包括炎症区和骨硬化区的表现定义为Ⅱ类病理特征，而包括炎症区、骨硬化区和骨反应带的表现定义为Ⅲ类病理特征。18例颌骨刮治术患者病理特征分布如下：Ⅰ类38.9%(7/18)，Ⅱ类44.4%(8/18)，Ⅲ类16.7%(3/18)。5例患者采用颌骨区段截骨术治疗，术后完全愈合。18例患者采用颌骨刮治术治疗，术后完全愈合的患者中病理特征分别为Ⅰ类2例，Ⅱ类和Ⅲ类各1例；而术后出现MRONJ复发的患者中病理特征分别为Ⅰ类5例，Ⅱ类7例和Ⅲ类2例。结论: MRONJ病变由浅至深的病理表现可分为炎症区、骨硬化区、骨反应带；颌骨刮治术治疗MRONJ复发的常见原因可能为术中未充分去除骨硬化区，而遗留的骨硬化区可能阻断了骨创愈合所需要的血运、营养因子及间充质干细胞。

关键词: 药物相关颌骨骨坏死, 病理特征, 颌骨刮治术, 颌骨区段截骨术

Abstract:

Objective: To summarize the pathological characteristics of medication-related osteonecrosis of the jaw (MRONJ) specimens after jaw curettage or jaw osteotomy treatment and to comprehensively analyze the relationship between the different pathological features, treatment methods, and treatment effects to provide new ideas for effective treatment of MRONJ in clinical work. Methods: The clinical and pathological data were collected from 23 patients with MRONJ who were treated with curettage (18 patients) and jaw osteotomy (5 patients) at the Department of Oral and Maxillofacial Surgery of Peking University Hospital of Stomatology between June 2014 and December 2015. The pathological characteristics of MRONJ were summarized and analyzed with treatment effects based on various surgical treatment methods. The diagnostic criteria and disease staging of MRONJ were determined according to the 2014 American Association of Oral and Maxillofacial Surgeon's Position Paper. Results: In this study, 5 patients have treated with jaw segmental osteotomy, and all of them were in stage Ⅲ; the other 18 patients were treated with jaw curettage, including 5 patients in stage Ⅱ and 13 patients in stage Ⅲ. The pathological features of MRONJ in five cases of jaw segmental osteotomy were divided into three adjacent regions from shallow to deep: inflammation region (IR), sclerosis region (SR), and bone remodeling layer (BRL). Moreover, three types of pathological features of specimens from traditional curettage were defined as type 1 (IR), type 2 (IR + SR), and type 3 (IR + SR + BRL). The pathological features of the patients treated with jaw curettage were: type Ⅰ, 38.9% (7/18); type Ⅱ, 44.4% (8/18); type Ⅲ, 16.7% (3/18). Complete healing was achieved in 5 patients treated with jaw segmental osteo-tomy. Moreover, 2 cases with type Ⅰ, 1 case with type Ⅱ, and 1 with type Ⅲ completely healed after jaw curettage, while 5 cases with type Ⅰ, 7 cases with type Ⅱ, and 2 cases with type Ⅲ experienced recurrence after surgery. Conclusion: Pathological features of continuous regions of inflammation, sclerosis, and bone remodeling layer were identified from shallow to deep, based on the microscopic observation of jaw segmental osteotomy samples. Insufficient removal of the sclerotic region during jaw curettage that blocks the required blood, nutritional factors, and mesenchymal stem cells seems to be a common cause for failed treatment of MRONJ after curettage surgery.

Key words: Medication-related osteonecrosis of the jaw, Pathological characteristics, Jaw curettage, Jaw segmental osteotomy

中图分类号: 

  • R782.4

表1

患者临床资料"

Items Clinical data (n=23)
Male/female, n 11/12
Age/years
  Mean 61.04
  Range 44-81
≥50 years, n 16
< 50 years, n 7
Type of cancer, n
  Breast 9
  Kidney 6
  Prostate 2
  Lung 2
  Bladder 2
  Esophageal 1
  Multiple myeloma 1
Antiresorptive therapy/month
  Mean duration of antiresorptive therapy before first visit 41.13±25.26(range: 10-96)
Type of antiresorptive therapy, n
  Zoledronate 10
  Pamidronate 10
  Zoledronate + pamidronate 3
Mean duration of clinical symptoms before treatment/month 13.78±19.84(range: 2-96)
Trigger of MRONJ lesion, n
  Extraction 17
  Spontaneous 6
MRONJ location, n
  Maxilla 8
  Mandible 11
  Both maxilla and mandible 4
MRONJ stage, n
  Grade 2 5
  Grade 3 18
Treatment methods, n
  Jaw curettage 18
  Jaw segmental osteotomy 5
Mean duration until MRONJ relapse post treatment/month 5.71±4.08(range: 1-15)

图1

药物相关颌骨骨坏死病理特征及分类"

图2

药物相关颌骨骨坏死手术标本病理特征分类与临床分期、治疗方法的相关性分析"

图3

牙源性感染引起药物相关颌骨骨坏死发病过程示意图"

1 Sacco R , Sacco N , Hamid U , et al. Microsurgical reconstruction of the jaws using vascularised free flap technique in patients with medication-related osteonecrosis: A systematic review[J]. Biomed Res Int, 2018, 2018, 9858921.
2 Rupel K , Ottaviani G , Gobbo M , et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ)[J]. Oral Oncol, 2014, 50 (11): 1049- 1057.
doi: 10.1016/j.oraloncology.2014.08.016
3 郭玉兴, 王佃灿, 王洋, 等. 二膦酸盐药物治疗乳腺癌骨转移发生颌骨坏死的临床特点[J]. 北京大学学报(医学版), 2016, 48 (1): 80- 83.
doi: 10.3969/j.issn.1671-167X.2016.01.014
4 Hayashida S , Soutome S , Yanamoto S , et al. Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: A multicenter retrospective study with propensity score matching analysis[J]. J Bone Miner Res, 2017, 32 (10): 2022- 2029.
doi: 10.1002/jbmr.3191
5 Ruggiero SL , Dodson TB , Fantasia J , et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update[J]. J Oral Maxillofac Surg, 2014, 72 (10): 1938- 1956.
doi: 10.1016/j.joms.2014.04.031
6 Basi DL , Hughes PJ , Thumbigere-Math V , et al. Matrix metalloproteinase-9 expression in alveolar extraction sockets of Zoledronic acid-treated rats[J]. J Oral Maxillofac Surg, 2011, 69 (11): 2698- 2707.
doi: 10.1016/j.joms.2011.02.065
7 Yamashita J , Koi K , Yang DY , et al. Effect of zoledronate on oral wound healing in rats[J]. Clin Cancer Res, 2011, 17 (6): 1405- 1414.
doi: 10.1158/1078-0432.CCR-10-1614
8 Marx RE . Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: A growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61 (9): 1115- 1117.
doi: 10.1016/S0278-2391(03)00720-1
9 Ruggiero SL , Mehrotra B , Rosenberg TJ , et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases[J]. J Oral Maxillofac Surg, 2004, 62 (5): 527- 534.
doi: 10.1016/j.joms.2004.02.004
10 Lin JT , Lane JM . Bisphosphonates[J]. J Am Acad Orthop Surg, 2003, 11 (1): 1- 4.
doi: 10.5435/00124635-200301000-00001
11 Di Fede O , Panzarella V , Mauceri R , et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention[J]. Biomed Res Int, 2018, 2018, 2684924.
12 Shintani T , Hayashido Y , Mukasa H , et al. Comparison of the prognosis of bisphosphonate-related osteonecrosis of the jaw caused by oral and intravenous bisphosphonates[J]. Int J Oral Maxillofac Surg, 2015, 44 (7): 840- 844.
doi: 10.1016/j.ijom.2015.03.013
13 Nicolatou-Galitis O , Papadopoulou E , Vardas E , et al. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents[J]. Oral Dis, 2020, 26 (5): 955- 966.
doi: 10.1111/odi.13294
14 Guo Y , Guo C . Enhancement of bone perfusion through cortical perforations to improve healing of medication-related osteonecrosis of the jaw: A retrospective study[J]. Int J Oral Maxillofac Surg, 2021, 50 (6): 740- 745.
doi: 10.1016/j.ijom.2020.07.036
15 郭玉兴, 王佃灿, 刘筱菁, 等. 翻瓣联合骨管技术拔牙方案在药物相关性颌骨坏死潜在风险患者中的应用初探[J]. 中华口腔医学杂志, 2021, 56 (5): 452- 457.
doi: 10.3760/cma.j.cn112144-20210104-00003
[1] 刘帅,刘磊,刘茁,张帆,马潞林,田晓军,侯小飞,王国良,赵磊,张树栋. 伴静脉癌栓的肾上腺皮质癌的临床治疗及预后[J]. 北京大学学报（医学版）, 2024, 56(4): 624-630.
[2] 薛子璇,唐世英,邱敏,刘承,田晓军,陆敏,董靖晗,马潞林,张树栋. 青年肾肿瘤伴瘤栓的临床病理特征及预后分析[J]. 北京大学学报（医学版）, 2023, 55(5): 802-811.
[3] 赖玉梅,李忠武,李欢,吴艳,时云飞,周立新,楼雨彤,崔传亮. 68例肛管直肠黏膜黑色素瘤临床病理特征及预后[J]. 北京大学学报（医学版）, 2023, 55(2): 262-269.
[4] 朱晓娟,张虹,张爽,李东,李鑫,徐玲,李挺. 人表皮生长因子受体2低表达乳腺癌的临床病理学特征及预后[J]. 北京大学学报（医学版）, 2023, 55(2): 243-253.
[5] 李志华,徐纯如,刘颖,贯华,张萌,车新艳,唐琦,黄燕波,李学松,周利群. 饮水习惯与上尿路尿路上皮癌病理特征的相关性分析[J]. 北京大学学报（医学版）, 2022, 54(4): 621-627.
[6] 丁婷婷,曾楚雄,胡丽娜,余明华. 基于癌症基因组图谱数据库结直肠癌免疫细胞浸润预测模型的建立[J]. 北京大学学报（医学版）, 2022, 54(2): 203-208.
[7] 王迎春,黄永辉,常虹,姚炜,闫秀娥,李柯,张耀鹏,郑炜. 十二指肠乳头息肉良、恶性病变比较及活检准确性[J]. 北京大学学报（医学版）, 2021, 53(1): 204-209.
[8] 王文鹏,王捷夫,胡均,王俊锋,刘嘉,孔大陆,李健. 结直肠间质瘤临床病理特征及预后分析[J]. 北京大学学报（医学版）, 2020, 52(2): 353-361.
[9] 张晓鹏,黄子雄,于路平,张晓威,李清,刘士军,徐涛. 小肾细胞癌的临床与病理特征分析[J]. 北京大学学报（医学版）, 2019, 51(4): 623-627.
[10] 杨阳,刘毅强,王晓红,季科,李忠武,白健,杨爱蓉,胡颖,韩海勃,李子禹,步召德,吴晓江,张连海,季加孚. 单中心大样本Epstein-Barr病毒相关性胃癌亚型的临床病理及分子特征分析[J]. 北京大学学报（医学版）, 2019, 51(3): 451-458.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 钟金晟, 欧阳翔英, 梅芳, 邓旭亮, 曹采方. 多孔β-磷酸三钙/胶原支架与犬牙周膜细胞三维复合体的构建[J]. 北京大学学报（医学版）, 2007, 39(5): 507 -510 .
[2] 张奇, 罗国安, 邓英杰. 均匀设计法制备5-氟尿嘧啶脂质体及其稳定性[J]. 北京大学学报（医学版）, 2002, 34(1): 64 -67 .
[3] 管宏, 赵慧云, 沈磊, 李五岭, 王建华, 王春荣, 徐福. 联合应用重组TPO和G-CSF对骨髓抑制性小鼠外周血小板及白细胞恢复的影响[J]. 北京大学学报（医学版）, 2001, 33(2): 181 -182 .
[4] 林涛, 李琳丽, 詹先成, 李开兰, 李志毅, 殷恭宽. 盐酸普鲁卡因注射液在光和热同时作用下的稳定性[J]. 北京大学学报（医学版）, 2001, 33(3): 247 -250 .
[5] 李云芳, 张幼怡, 侯嵘, 董尔丹, 韩启德. 质粒转染对HEK293和DDT1-MF2细胞天然β2-肾上腺素受体表达的影响[J]. 北京大学学报（医学版）, 2001, 33(5): 457 -461 .
[6] 柯杨. 乳头状瘤病毒与人类肿瘤[J]. 北京大学学报（医学版）, 2002, 34(5): 599 -603 .
[7] 赵建新, 周良, 万远廉. 经十二指肠逆行放置支架治疗恶性幽门梗阻2例[J]. 北京大学学报（医学版）, 2002, 34(6): 737 -738 .
[8] 洪涛, 霍勇. COURAGE试验后稳定型心绞痛的治疗策略思考[J]. 北京大学学报（医学版）, 2007, 39(6): 562 -564 .
[9] 牟向东, 王广发, 阙呈立, 李桂莲. H3N2型人流行性感冒合并金黄色葡萄球菌败血症及金黄色葡萄球菌肺炎1例[J]. 北京大学学报（医学版）, 2007, 39(6): 663 -665 .
[10] 李智岗, 黄景香, 李顺宗, 赵俊京, 时高峰, 梁国庆, 王红光, 韩捧银, 王琦, 谷铁树. 肝转移瘤的血供[J]. 北京大学学报（医学版）, 2008, 40(2): 146 -150 .
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部